|Nom||Titre||Payer||Exercé||Année de naissance|
|Dr. Severin Schwan Ph.D.||CEO & Exec. Director||7,52M||S.O.||1967|
|Dr. Alan Hippe||Chief Financial & Information Officer||4,31M||S.O.||1967|
|Ms. Cristina A. Wilbur||Chief People Officer||3,09M||S.O.||1967|
|Dr. Johannes Carolus Clevers M.D., Ph.D.||Head of Roche Pharma Research & Early Devel.||350,11k||S.O.||1957|
|Dr. Thomas Schinecker||Chief Exec. Officer of Roche Diagnostics||2,95M||S.O.||1975|
|Mr. William N. Anderson||Chief Exec. Officer of Roche Pharmaceuticals||6,49M||S.O.||1966|
|Dr. Karl Mahler||Head of Investor Relations||S.O.||S.O.||S.O.|
|Ms. Claudia Bockstiegel||Gen. Counsel||S.O.||S.O.||1964|
|Ms. Pascale Schmidt||Chief Compliance Officer||S.O.||S.O.||1973|
|Ms. Barbara Schadler||Head of Group Communications||S.O.||S.O.||1962|
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, the company supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. It has collaboration with Gilead Sciences, Inc. for COVID-19; and a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza. The company also has a collaboration with Bristol Myers Squibb to advance personalized healthcare through digital pathology solutions. The company was founded in 1896 and is headquartered in Basel, Switzerland.
L’ISS Governance QualityScore de Roche Holding AG en date du 1 mai 2022 est 9. Les scores principaux sont Audit : 10; Société : 6; Droits des actionnaires : 1; Compensation : 9.